ResearchPUBMED3 days ago
Scientists are studying a new type of medicine made from circular RNA, which is RNA shaped like a circle instead of a line. Because of their circular shape, these medicines may stay in the body longer and work better than current RNA medicines. Researchers are testing these circular RNA medicines to treat cancer, immune system diseases, and rare diseases.
WHY IT MATTERSCircular RNA therapeutics could eventually offer longer-lasting treatments for rare diseases with fewer doses needed, but patients should know that claims about safety and effectiveness vary depending on how the medicine is made—there's no one-size-fits-all answer yet.
ResearchPUBMEDApr 14
Scientists have discovered that certain rare genetic diseases are caused by mutations in genes that help cells copy their DNA. These genes normally produce proteins that untangle special twisted DNA structures called G-quadruplexes that get in the way during copying. When these proteins don't work properly, cells can't copy their DNA correctly, leading to problems like weak immune systems, slow growth, birth defects, and increased cancer risk.
WHY IT MATTERSUnderstanding which genes cause these G-quadruplex problems could help doctors diagnose patients with unexplained immunodeficiency, growth delays, or birth defects, and may eventually lead to targeted treatments for these currently untreatable conditions.
ResearchPUBMEDApr 10
Doctors from around the world created a network called the International Neuroblastoma Risk Group to share information about neuroblastoma, a type of cancer that starts in nerve cells. They combined data from over 25,000 patients to help researchers understand the disease better and develop better treatment plans. This teamwork model shows how rare cancer research can be improved when hospitals and countries work together.
WHY IT MATTERSPatients with neuroblastoma now benefit from standardized treatment approaches and risk classifications developed through this international collaboration, which means more consistent and potentially better care regardless of where they receive treatment.
ResearchPUBMEDApr 1
Researchers reviewed 78 studies about early satiety (feeling full quickly after eating small amounts) in cancer patients. They found this symptom is common but often overlooked, and doctors don't have consistent ways to measure or describe it. The review shows there are big gaps in how we understand and treat this problem for cancer patients.
WHY IT MATTERSEarly satiety causes cancer patients to eat less and lose weight, which can weaken their ability to fight cancer and recover from treatment—but doctors rarely screen for or address this specific symptom.
ResearchPUBMEDApr 1
Researchers studied whether the amount of cancer in a patient's body before treatment affects how well two immunotherapy drugs work together. They looked at 722 patients with rare cancers who received nivolumab and ipilimumab (two drugs that help the immune system fight cancer). The study wanted to understand if patients with smaller tumors do better than those with larger tumors when treated with these combination drugs.
WHY IT MATTERSIf baseline tumor size predicts treatment response in rare cancers, doctors could better counsel patients on expected outcomes and identify which patients might benefit most from this dual immunotherapy approach before starting treatment.
ResearchPUBMEDMar 26
Scientists are developing tiny particles called exosomes that can deliver cancer-fighting medicines directly to rare cancer tumors. These natural particles act like delivery trucks, carrying drugs to cancer cells while reducing damage to healthy cells. Early research shows this approach could help rare cancer patients who currently have few treatment options.
WHY IT MATTERSPatients with rare cancers often lack targeted treatments and face delayed diagnoses—exosome-based therapies could provide new options by delivering drugs more effectively to tumors while causing fewer side effects.
ResearchPUBMEDMar 26
Researchers in China studied 26 children and young adults (average age 8 years old) who had a rare cancer called rhabdomyosarcoma that started in the female reproductive organs. They tracked these patients for an average of nearly 5 years to see how well different treatments worked. This study helps doctors understand the best ways to treat this uncommon type of cancer in girls and young women.
WHY IT MATTERSThis is the first large study from China showing long-term survival rates for girls with genital rhabdomyosarcoma, which can help doctors worldwide improve treatment plans and give families more accurate information about what to expect.
ResearchPUBMEDMar 26
Scientists studying a rare childhood cancer called alveolar rhabdomyosarcoma have discovered how cancer cells make extra copies of certain genes that help them grow. They found that different parts of chromosomes (the structures that hold our genes) get copied in different ways—some amplify just one gene, while others amplify multiple genes at once. Understanding these patterns helps doctors figure out which patients might need different treatments.
WHY IT MATTERSThis research identifies specific genetic changes in rhabdomyosarcoma that could lead to targeted treatments tailored to each patient's tumor genetics, potentially improving survival rates for children with this aggressive cancer.
ResearchPUBMEDMar 26
Researchers studied how cancer tumors respond differently to a two-drug immunotherapy treatment (ipilimumab plus nivolumab) in patients with rare cancers. Some patients had some tumors shrink while others grew at the same time—called 'mixed response.' This study looked at 438 patients to understand how this mixed response affects how long patients survive and whether the cancer comes back.
WHY IT MATTERSUnderstanding mixed response patterns helps doctors better predict which rare cancer patients will benefit most from dual checkpoint inhibitor therapy and may improve how treatment success is measured beyond just tumor size.
ResearchPUBMEDMar 26
A 45-year-old man had ear canal swelling and an ear infection that wouldn't go away with normal treatment. Doctors performed surgery but didn't find the cause at first. After more testing, they discovered the real problem: cancer cells from a blood disease called acute myeloid leukemia (AML) had come back and were growing in the bone behind his ear.
WHY IT MATTERSThis case shows that persistent ear infections that don't respond to standard treatment could be a sign of leukemia relapse, meaning AML patients with unusual ear symptoms need urgent investigation beyond typical infection treatment.
ResearchPUBMEDMar 26
Doctors found a very rare type of cancer in a woman's urethra (the tube that carries urine out of the body). This cancer, called clear cell adenocarcinoma, is so uncommon that only a few cases have ever been reported. The article describes how doctors used special imaging scans (MRI and PET/CT) to find and diagnose this cancer.
WHY IT MATTERSThis case report helps doctors recognize and diagnose primary clear cell adenocarcinoma of the female urethra earlier, since it's so rare that many physicians may never encounter it in their careers.
ResearchCLINICALTRIALSMar 26
Researchers are studying 1,000 children and adults with adrenocortical carcinoma (ACC), a rare cancer of the adrenal glands. They want to understand why some people survive longer than others and whether certain treatments work better. The average person with ACC lives about 14.5 months after diagnosis, but survival times vary widely.
WHY IT MATTERSThis study is actively collecting data that could help doctors better predict outcomes and choose more effective treatments for ACC patients, though it is not currently recruiting new participants.
ResearchCLINICALTRIALSMar 26
Researchers at the National Cancer Institute completed a study of 326 people with rare brain and spine tumors, including meningioma, ependymoma, medulloblastoma, and other types. The study collected health information and genetic data to understand what causes these tumors to develop and what factors increase the risk of getting them. These tumors are very uncommon, affecting fewer than 2,000 people per year in the United States.
WHY IT MATTERSThis completed study provides researchers with genetic and health data from 326 patients that could lead to better understanding of why these rare brain tumors develop, potentially informing future treatment options and risk screening for patients with these conditions.